{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:01:54Z","timestamp":1793282514004,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Osteoprotegerin (OPG) and osteopontin (OPN) are vascular calcification inhibitors with a known role in the atherosclerotic and inflammatory process. We investigated their relationship with adverse outcomes (restenosis\/adverse cardiovascular events) after endovascular revascularisation of patients with peripheral arterial disease (PAD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>203 consecutive patients were enrolled in the PAD group (PADG) and 78 age and sex-matched subjects with less than two cardiovascular risk factors served as control group (COG). PADG underwent standard medical assessment at baseline and 12\u00a0months after the procedure. During follow up major adverse cardiovascular events (MACEs) including arterial restenosis with need for reintervention were documented and the PADG was divided accordingly into two subgroups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During 12-month follow-up, 82 MACE were recorded (MACE subgroup). The rest of 124 PAD patients remained free of MACE (non-MACE subgroup). At baseline, OPG (9.89\u2009\u00b1\u20092.85\u00a0ng\/ml vs 3.47\u2009\u00b1\u20091.95\u00a0ng\/ml, p\u2009&lt;\u20090.001) and OPN (79.99\u2009\u00b1\u200938.29\u00a0ng\/ml vs 35.21\u2009\u00b1\u200914.84\u00a0ng\/ml, p\u2009&lt;\u20090.001) levels were significantly higher in PADG compared to COG, as well as in MACE subgroup compared to non-MACE subgroup (13.29\u2009\u00b1\u20093.23\u00a0ng\/ml vs 10.86\u2009\u00b1\u20093\u00a0ng\/ml and 96.45\u2009\u00b1\u200940.12\u00a0ng\/ml vs 78.1\u2009\u00b1\u200938.29\u00a0ng\/ml, respectively). An independent association of PAD with OPG and OPN was found in the whole patient cohort. Although OPG and OPN were significantly related to MACE incidence in the univariate analysis, multiple logistic regression analysis failed to detect any independent predictor of MACE within the PADG.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Baseline high OPG and OPN levels were independently associated with PAD presence. Even higher levels of those biomarkers were detected among PAD patients with MACE, however, their prognostic role should be further clarified.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-022-01605-6","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T19:05:48Z","timestamp":1662059148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Association of serum levels of osteopontin and osteoprotegerin with adverse outcomes after endovascular revascularisation in peripheral artery disease"],"prefix":"10.1186","volume":"21","author":[{"given":"Nikolaos P. E.","family":"Kadoglou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Kapetanios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Korakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Valsami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Tentolouris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaia","family":"Lambadiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Karkos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"key":"1605_CR1","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/archinte.163.8.884","volume":"163","author":"JJ Belch","year":"2003","unstructured":"Belch JJ, Topol EJ, Agnelli G, et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med. 2003;163:884\u201392.","journal-title":"Arch Intern Med"},{"issue":"4","key":"1605_CR2","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.3390\/ijms22042002","volume":"22","author":"F Biscetti","year":"2021","unstructured":"Biscetti F, Nardella E, Rando MM, et al. Outcomes of lower extremity endovascular revascularization: potential predictors and prevention strategies. Int J Mol Sci. 2021;22(4):2002.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1605_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.avsg.2012.02.027","volume":"27","author":"S Bleda","year":"2013","unstructured":"Bleda S, De Haro J, Acin F, Varela C, Esparza L, L\u00f3pez de Maturana I. Infammatory burden predicts long-term outcomes in endovascular therapy in peripheral arterial disease. Ann Vasc Surg. 2013;27(4):459\u201366.","journal-title":"Ann Vasc Surg"},{"issue":"19","key":"1605_CR4","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.jacc.2010.03.013","volume":"55","author":"SM Venuraju","year":"2010","unstructured":"Venuraju SM, Yerramasu A, Corder R, Lahiri A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol. 2010;55(19):2049\u201361.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1605_CR5","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1161\/ATVBAHA.118.311577","volume":"39","author":"ZSY Lok","year":"2019","unstructured":"Lok ZSY, Lyle AN. Osteopontin in vascular disease. Arterioscler Thromb Vasc Biol. 2019;39(4):613\u201322.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"1605_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3109\/14017431.2012.685491","volume":"46","author":"SE Hosbond","year":"2012","unstructured":"Hosbond SE, Poulsen TS, Diederichsen AC, Nybo M, Rasmussen LM, Mickley H. Osteoprotegerin as a marker of atherosclerosis: a systematic update. Scand Cardiovasc J. 2012;46(4):203\u201311.","journal-title":"Scand Cardiovasc J"},{"issue":"9","key":"1605_CR7","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","volume":"12","author":"N Bucay","year":"1998","unstructured":"Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12(9):1260\u20138.","journal-title":"Genes Dev"},{"key":"1605_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1475-2840-10-76","volume":"10","author":"MK Poulsen","year":"2011","unstructured":"Poulsen MK, Nybo M, Dahl J, et al. Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus. Cardiovasc Diabetol. 2011;10:76.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"1605_CR9","doi-asserted-by":"publisher","first-page":"e423","DOI":"10.1016\/j.thromres.2010.09.003","volume":"126","author":"EP O'Sullivan","year":"2010","unstructured":"O\u2019Sullivan EP, Ashley DT, Davenport C, et al. Osteoprotegerin is higher in peripheral arterial disease regardless of glycaemic status. Thromb Res. 2010;126(6):e423\u20137.","journal-title":"Thromb Res"},{"issue":"1","key":"1605_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.atherosclerosis.2005.01.042","volume":"182","author":"S Ziegler","year":"2005","unstructured":"Ziegler S, Kudlacek S, Luger A, Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis. 2005;182(1):175\u201380.","journal-title":"Atherosclerosis"},{"issue":"3","key":"1605_CR11","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ejvs.2009.11.013","volume":"39","author":"NP Kadoglou","year":"2010","unstructured":"Kadoglou NP, Gerasimidis T, Kapelouzou A, et al. Beneficial changes of serum calcification markers and contralateral carotid plaques echogenicity after combined carotid artery stenting plus intensive lipid-lowering therapy in patients with bilateral carotid stenosis. Eur J Vasc Endovasc Surg. 2010;39(3):258\u201365.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"1605_CR12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12872-015-0079-0","volume":"15","author":"Y Niu","year":"2015","unstructured":"Niu Y, Zhang W, Yang Z, et al. Association of plasma osteoprotegerin levels with the severity of lower extremity arterial disease in patients with type 2 diabetes. BMC Cardiovasc Disord. 2015;15:86.","journal-title":"BMC Cardiovasc Disord"},{"issue":"8\u20139","key":"1605_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.acvd.2015.01.015","volume":"108","author":"A Esteghamati","year":"2015","unstructured":"Esteghamati A, Aflatoonian M, Rad MV, et al. Association of osteoprotegerin with peripheral artery disease in patients with type 2 diabetes. Arch Cardiovasc Dis. 2015;108(8\u20139):412\u20139.","journal-title":"Arch Cardiovasc Dis"},{"issue":"10","key":"1605_CR14","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.2337\/dc19-0408","volume":"42","author":"F Biscetti","year":"2019","unstructured":"Biscetti F, Ferraro PM, Hiatt WR, et al. Inflammatory cytokines associated with failure of lower-extremity endovascular revascularization (LER): a prospective study of a population with diabetes. Diabetes Care. 2019;42(10):1939\u201345.","journal-title":"Diabetes Care"},{"issue":"16","key":"1605_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009012","volume":"7","author":"L Tschiderer","year":"2018","unstructured":"Tschiderer L, Klingenschmid G, Nagrani R, et al. Osteoprotegerin and cardiovascular events in high-risk populations: meta-analysis of 19 prospective studies involving 27,450 participants. J Am Heart Assoc. 2018;7(16): e009012.","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"1605_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183910","volume":"12","author":"L Tschiderer","year":"2017","unstructured":"Tschiderer L, Willeit J, Schett G, Kiechl S, Willeit P. Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: literature-based meta-analysis involving 26,442 participants. PLoS ONE. 2017;12(8): e0183910.","journal-title":"PLoS ONE"},{"issue":"7","key":"1605_CR17","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3390\/biom11071047","volume":"11","author":"K Shirakawa","year":"2021","unstructured":"Shirakawa K, Sano M. Osteopontin in cardiovascular diseases. Biomolecules. 2021;11(7):1047.","journal-title":"Biomolecules"},{"issue":"5","key":"1605_CR18","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.ijcard.2012.05.001","volume":"167","author":"D Tousoulis","year":"2013","unstructured":"Tousoulis D, Siasos G, Maniatis K, et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol. 2013;167(5):1924\u20138.","journal-title":"Int J Cardiol"},{"issue":"4","key":"1605_CR19","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1365-2362.2010.02257.x","volume":"40","author":"P Georgiadou","year":"2010","unstructured":"Georgiadou P, Iliodromitis EK, Kolokathis F, et al. Osteopontin as a novel prognostic marker in stable ischaemic heart disease: a 3-year follow-up study. Eur J Clin Invest. 2010;40(4):288\u201393.","journal-title":"Eur J Clin Invest"},{"issue":"7","key":"1605_CR20","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/eurheartj\/ehi730","volume":"27","author":"P Minoretti","year":"2006","unstructured":"Minoretti P, Falcone C, Calcagnino M, et al. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J. 2006;27(7):802\u20137.","journal-title":"Eur Heart J"},{"issue":"6","key":"1605_CR21","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1177\/2047487313487083","volume":"20","author":"M Bjerre","year":"2013","unstructured":"Bjerre M, Pedersen SH, M\u00f8gelvang R, et al. High osteopontin levels predict long-term outcome after STEMI and primary percutaneous coronary intervention. Eur J Prev Cardiol. 2013;20(6):922\u20139.","journal-title":"Eur J Prev Cardiol"},{"issue":"9","key":"1605_CR22","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2217\/bmm-2018-0458","volume":"13","author":"JF Lin","year":"2019","unstructured":"Lin JF, Wu S, Juang JJ, et al. Osteoprotegerin and osteopontin levels, but not gene polymorphisms, predict mortality in cardiovascular diseases. Biomark Med. 2019;13(9):751\u201360.","journal-title":"Biomark Med"},{"issue":"2","key":"1605_CR23","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1177\/1534734619898097","volume":"19","author":"I Eleftheriadou","year":"2020","unstructured":"Eleftheriadou I, Tsilingiris D, Tentolouris A, et al. Association of circulating osteopontin levels with lower extremity arterial disease in subjects with type 2 diabetes mellitus: a cross-sectional observational study. Int J Low Extrem Wounds. 2020;19(2):180\u20139.","journal-title":"Int J Low Extrem Wounds"},{"issue":"1","key":"1605_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/0003319708314250","volume":"60","author":"M Koshikawa","year":"2009","unstructured":"Koshikawa M, Aizawa K, Kasai H, et al. Elevated osteopontin levels in patients with peripheral arterial disease. Angiology. 2009;60(1):42\u20135.","journal-title":"Angiology"},{"issue":"6","key":"1605_CR25","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/ajh.2010.38","volume":"23","author":"M Zagura","year":"2010","unstructured":"Zagura M, Serg M, Kampus P, et al. Association of osteoprotegerin with aortic stiffness in patients with symptomatic peripheral artery disease and in healthy subjects. Am J Hypertens. 2010;23(6):586\u201391.","journal-title":"Am J Hypertens"},{"issue":"1","key":"1605_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12933-021-01411-6","volume":"20","author":"NPE Kadoglou","year":"2021","unstructured":"Kadoglou NPE, Korakas E, Karkos C, et al. The prognostic role of RBP-4 and adiponectin in patients with peripheral arterial disease undergoing lower limb endovascular revascularization. Cardiovasc Diabetol. 2021;20(1):221.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1605_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ejvs.2014.10.009","volume":"49","author":"NP Kadoglou","year":"2015","unstructured":"Kadoglou NP, Sfyroeras GS, Spathis A, et al. Galectin-3, carotid plaque vulnerability, and potential effects of statin therapy. Eur J Vasc Endovasc Surg. 2015;49(1):4\u20139.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"1605_CR28","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1210\/jc.2002-020775","volume":"88","author":"M Schoppet","year":"2003","unstructured":"Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab. 2003;88:1024\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"1605_CR29","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","volume":"45","author":"L Norgren","year":"2007","unstructured":"Norgren L, Hiatt WR, Dormandy J, Nehler MR, Harris K, Fowkes FGR. Intersociety consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45:S5-67.","journal-title":"J Vasc Surg"},{"issue":"1","key":"1605_CR30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12933-017-0581-z","volume":"16","author":"S Giovannini","year":"2017","unstructured":"Giovannini S, Tinelli G, Biscetti F, et al. Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects. Cardiovasc Diabetol. 2017;16(1):99.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1605_CR31","first-page":"56","volume":"1","author":"X Wang","year":"2021","unstructured":"Wang X, Teng Q, Zhu L. Risk factors for development of PAD in PD patients. Iran J Kidney Dis. 2021;1(1):56\u201360.","journal-title":"Iran J Kidney Dis"},{"issue":"2","key":"1605_CR32","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.atherosclerosis.2010.06.027","volume":"212","author":"ER Pedersen","year":"2010","unstructured":"Pedersen ER, Ueland T, Seifert R, et al. Serum osteoprotegerin levels and long-term prognosis in patients with stable angina pectoris. Atherosclerosis. 2010;212(2):644\u20139.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1605_CR33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12933-021-01304-8","volume":"20","author":"F Biscetti","year":"2021","unstructured":"Biscetti F, Tinelli G, Rando MM, et al. Association between carotid plaque vulnerability and high mobility group box-1 serum levels in a diabetic population. Cardiovasc Diabetol. 2021;20(1):114.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"1605_CR34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40261-013-0157-y","volume":"34","author":"NP Kadoglou","year":"2014","unstructured":"Kadoglou NP, Kottas G, Lampropoulos S, Vitta I, Liapis CD. Serum levels of fetuin-A, osteoprotegerin and osteopontin in patients with coronary artery disease: effects of statin (HMGCoA-reductase inhibitor) therapy. Clin Drug Investig. 2014;34(3):165\u201371.","journal-title":"Clin Drug Investig"},{"key":"1605_CR35","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ejvs.2007.12.011","volume":"35","author":"NPE Kadoglou","year":"2008","unstructured":"Kadoglou NPE, Gerasimidis T, Moumtzouoglou A, et al. Intensive lipid-lowering therapy ameliorates novel calcification markers and GSM score in patients with carotid stenosis. Eur J Vasc Endovasc Surg. 2008;35:661\u20138.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"1605_CR36","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/ijc.21606","volume":"118","author":"SS Cross","year":"2006","unstructured":"Cross SS, Yang Z, Brown NJ, et al. Osteoprotegerin (OPG): a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer. 2006;118:1901\u20138.","journal-title":"Int J Cancer"},{"key":"1605_CR37","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1161\/01.RES.0000149165.99974.12","volume":"95","author":"P Collin-Osdoby","year":"2004","unstructured":"Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors rankl and osteoprotegerin. Circ Res. 2004;95:1046\u201357.","journal-title":"Circ Res"},{"issue":"3","key":"1605_CR38","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.cardiores.2007.07.017","volume":"76","author":"SH Mangan","year":"2007","unstructured":"Mangan SH, Van Campenhout A, Rush C, Golledge J. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. Cardiovasc Res. 2007;76(3):494\u2013505.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"1605_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.atherosclerosis.2011.05.019","volume":"218","author":"B Toffoli","year":"2011","unstructured":"Toffoli B, Pickering RJ, Tsorotes D, et al. Osteoprotegerin promotes vascular fibrosis via a TGF-\u03b21 autocrine loop. Atherosclerosis. 2011;218(1):61\u20138.","journal-title":"Atherosclerosis"},{"issue":"6","key":"1605_CR40","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.2353\/ajpath.2006.060398","volume":"169","author":"PL Secchiero","year":"2006","unstructured":"Secchiero PL, Corallini F, Pandolfi A, et al. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol. 2006;169(6):2236\u201344.","journal-title":"Am J Pathol"},{"issue":"6","key":"1605_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156965","volume":"11","author":"AD Abdalrhim","year":"2016","unstructured":"Abdalrhim AD, Marroush TS, Austin EE, et al. Plasma osteopontin levels and adverse cardiovascular outcomes in the PEACE trial. PLoS ONE. 2016;11(6): e0156965.","journal-title":"PLoS ONE"},{"issue":"1","key":"1605_CR42","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/01.ATV.0000200224.48947.a6","volume":"26","author":"R Kato","year":"2006","unstructured":"Kato R, Momiyama Y, Ohmori R, et al. High plasma levels of osteopontin in patients with restenosis after percutaneous coronary intervention. Arterioscler Thromb Vasc Biol. 2006;26(1):e1-2.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"1605_CR43","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1253\/circj.CJ-08-0687","volume":"73","author":"R Kato","year":"2009","unstructured":"Kato R, Momiyama Y, Ohmori R, et al. Prognostic significance of plasma osteopontin levels in patients undergoing percutaneous coronary intervention. Circ J. 2009;73(1):152\u20137.","journal-title":"Circ J"},{"issue":"21","key":"1605_CR44","first-page":"00158","volume":"S0214\u20139168","author":"MA Behairy","year":"2022","unstructured":"Behairy MA, Shawky S, Hamed R, Bawady S, Abdelsattar HA, Bichari W. Is serum osteopontin a predictor of carotid atherosclerosis severity among prevalent hemodialysis patients? Clin Investig Arterioscler. 2022;S0214\u20139168(21):00158\u201363.","journal-title":"Clin Investig Arterioscler"},{"key":"1605_CR45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.atherosclerosis.2021.07.010","volume":"332","author":"Z Zhu","year":"2021","unstructured":"Zhu Z, He Y, Shi M, et al. Plasma osteopontin levels and adverse clinical outcomes after ischemic stroke. Atherosclerosis. 2021;332:33\u201340.","journal-title":"Atherosclerosis"},{"issue":"2","key":"1605_CR46","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.atherosclerosis.2014.07.004","volume":"236","author":"T Wolak","year":"2014","unstructured":"Wolak T. Osteopontin - a multi-modal marker and mediator in atherosclerotic vascular disease. Atherosclerosis. 2014;236(2):327\u201337.","journal-title":"Atherosclerosis"},{"issue":"5","key":"1605_CR47","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1161\/01.CIR.0000055739.13639.D7","volume":"107","author":"K Isoda","year":"2003","unstructured":"Isoda K, Kamezawa Y, Ayaori M, Kusuhara M, Tada N, Ohsuzu F. Osteopontin transgenic mice fed a high-cholesterol diet develop early fatty-streak lesions. Circulation. 2003;107(5):679\u201381.","journal-title":"Circulation"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01605-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-022-01605-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01605-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T21:02:48Z","timestamp":1662066168000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-022-01605-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1605"],"URL":"https:\/\/doi.org\/10.1186\/s12933-022-01605-6","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"assertion":[{"value":"23 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted according to the Declaration of Helsinki and was approved by the local ethics committees of all participating hospitals. Written informed consent was obtained from each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"171"}}